Pilot study of prolonged interferon-α retreatment in chronic hepatitis C patients with genotype 1b

Hepatology Research

Volumn 27, Issue 4, 2003, Pages 266-271

  Nomura, Hideyuki ^a   Tanimoto, Hironori ^a   Sou, Suketo ^a   Nagahama, Takashi ^a   Hayashi, Jun ^b   Kashiwagi, Seizaburo ^c   Ishibashi, Hiromi ^d  

^a Shin Kokura Hospital   (Japan)

^b KYUSHU UNIVERSITY HOSPITAL   (Japan)

^c Japanese Red Cross Kyushu Block Blood Center   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

Author keywords

Chronic hepatitis C; Genotype 1b; Long term follow up; Prolonged interferon therapy; Retreatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; LYMPHOBLAST INTERFERON; VIRUS RNA;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; FOLLOW UP; GENOTYPE; HEMATOLOGIC DISEASE; HEMOGLOBIN DETERMINATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; LIVER CELL CARCINOMA; LONG TERM CARE; MALAISE; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; RELAPSE; RETREATMENT; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; TREATMENT OUTCOME; VIRUS LOAD;

EID: 0346264729     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6346(03)00271-7     Document Type: Article

References (30)

1. Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990;12:671-5.
2. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alpha: a multi-center randomized, controlled trial. N Engl J Med 1989;321:1501-6.
3. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-10.
4. Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 1998;27:1394-402.
5. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med 1999;131:174-81.
6. Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999;29:1124-30.
7. Okanoue T, Itoh Y, Minami M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J Hepatol 1999;30:653-9.
8. Okanoue T, Itoh Y, Kirishima T, et al. Transient biochemical response in interferon therapy decreases the development of hepatocellular carcinoma for five years and improves the long-term survival of chronic hepatitis C patients. Hepatol Res 2002;23:62-77.
9. Hayashi J, Ohmiya M, Kishihara Y, et al. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenterol 1994;89:2151-6.
10. Yoshioka K, Kakumu S, Wakita. T, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus. Hepatology 1992;16:293-9.
11. Tsubota A, Chayama K, Ikeda K, et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994;19:1088-94.
12. Enomoto N, Takada A, Nakao T, Date T. There are two major types of hepatitis C virus in Japan. Biochem Biophys Res Commun 1990;16:1021-5.
13. Nomura H, Tsuchiya Y, Maruyama T, Miki K, Yokota T, Okubo H. The effects of a high dose, short course of interferon on hepatitis C. J Gastroenterol Hepatol 1999;14:85-9.
14. Nomura H, Kimura Y, Tada H, et al. Predictive factors of a response to interferon therapy in chronic hepatitis C. J Clin Gastroenterol 1996;23:185-90.
15. Watanabe H, Iwata K, Sohda T, Sakisaka S. Interferon beta induction/interferon alpha therapy in patients with interferon-resistant chronic hepatitis C. Hepatol Res 2002;24:355-60.
16. Suzuki H, Tango T. A multicenter, randomized, controlled clinical trial of interferon alfacon-1 in comparison with lymphoblastoid interferon-alpha in patients with high-titer chronic hepatitis C virus infection. Hepatol Res 2002;22:1-12.
17. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493-9.
18. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
19. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32.
20. Detmer J, Lagier R, Flynn J, et al. Accurate quantification of hepatitis C virus (HCV) RNA from all HCV-genotypes by using branched-DNA technology. J Clin Microbiol 1996;34:901-7.
21. Causse X, Godinot H, Chevallier M, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991;101:497-502.
22. Lau JYN, Davis GL, Kniffen J, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993;341:1501-4.
23. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Sheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-20.
24. Kasahara A, Hayashi N, Hiramatsu N, et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology 1995;21:291-7.
25. Iino S, Ichida F, Sakuma A, Suzuki H. Study group for chronic hepatitis C (OPC-18). A randomized clinical trial with natural interferon-alpha monotherapy for 24 or 48 weeks on patients with chronic hepatitis C having genotype 1b infection in high viral titers. Hepatol Res 2002;24:338-45.
26. Arase Y, Ikeda K, Tsubota A, et al. Randomized trial of prolonged interferon retreatment for chronic hepatitis C patients with HCV-genotype 1b and high virus load. Hepatol Res 2003;25:364-70.
27. Saracco G, Borghesio E, Mesina P, et al. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon α-2b for chronic hepatitis type C. J Hepatol 1997;27:56-62.
28. Iyoda K, Yuki N, Kato M, et al. Retreatment with interferon for chronic hepatitis C after transient response. J Clin Gastroenterol 2000;31:297-301.
29. Arase Y, Ikeda K, Murashima N, et al. The long-term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997;79:1494-500.
30. Kanai K, Kako M, Kumada T, et al. High-dose (9 MU) long-term (60 weeks) alfa-interferon therapy for chronic hepatitis patients infected with HCV genotype 1b. Arch Virol 1998;143:1545-54.